Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors

Annals of Oncology

Volumn 14, Issue 11, 2003, Pages 1682-1687

  Goel, S ^a   Bulgaru, A ^a   Hochster, H ^c   Wadler, S ^a   Zamboni, W ^d   Egorin, M ^d   Ivy, P ^e   Leibes, L ^c   Muggia, F ^c   Lockwood, G ^f   Harvey, E ^f   Renshaw, G ^g   Mani, S ^a,b,h  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Sanofi Synthelabo   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h Jack D Weiler Hospital   (United States)

Author keywords

5 fluorouracil; Gemcitabine; Oxaliplatin; Phase I; Solid tumors

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; DEOXYURIDINE PHOSPHATE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; AGED; ANEMIA; ARTICLE; ATAXIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; DYSESTHESIA; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; MALE; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SENSORY NEUROPATHY; SEPSIS; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 10744220591     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg453     Document Type: Article

References (26)

1. Huang P, Chubb S, Hertel LW et al. Action of 2′2′-difluoro-2′deoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-6117.
2. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
3. Heineman V, Xu YZ, Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CLM cells by 2,2-difluoro-2-deoxycytidine. Mol Pharmacol 1990; 38: 567-572.
4. Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro 2-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998; 4: 2811-2818.
5. Plunkett W, Huang P, Xu Y-Z et al. Gemcitabine: metabolism, mechanism of action and self-potentiation. Semin Oncol 1995; 22: 3-10.
6. Peters GJ, van der Wilt CL, van Moorsel et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87: 227-253.
7. Schulz L, Schalhorn A, Wilmanns W, Heinemann V. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells. Proc Am Soc Clin Oncol 1998; 17: 251a (Abstr 965).
8. Mani S, Vogelzang NJ, Bertucci D et al. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors. Cancer 2001; 92: 1567-1576.
9. Mani S, Graham MA, Bregman DB et al. Oxaliplatin: a review of evolving concepts. Cancer Invest 2002; 20: 246-263.
10. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996; 52: 1855-1865.
11. Raymond E, Buquet-Fagot C, Djelloul S et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 976-885.
12. Faivre S, Raymond E, Woynarowski JM et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-123.
13. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
14. Goldberg RM, Morton RF, Sargent DJ et al. N 9741: oxaliplatin or CPT-11 + 5-FU/leucovorin or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 2002; 21: 128a (Abstr 511).
15. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 2002; 13: 553-557.
16. Louvet C, Andre T, Lledo G et al. gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20: 1512-1518.
17. Mavroudis D, Kourousis C, Kakolyris S et al. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin Oncol 2000; 27 (Suppl 2): S25-S30.
18. Mani S, Manalo J, Bregman D. Novel combinations with oxaliplatin. Oncology (Huntingt) 2000; 14 (Suppl 11): 52-58.
19. Eli Lilly. Package insert for gemcitabine (Gemzar®). Indianapolis, IN: Eli Lilly.
20. Pharmacia and Upjohn. Package insert for 5-fluorouracil (Adrucil®). Kalamazoo, MI: Pharmacia and Upjohn.
21. Simon R, Freidlin B, Rubinstein L et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997; 89: 1138-1147.
22. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
23. Louvet C, Andre T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-4548.
24. Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17: 585-592.
25. Kollmannsberger C, Rick O, Derigs H-G et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German testicular cancer study group. J Clin Oncol 2002; 20: 2031-2037.
26. Becouarn Y, Agostini C, Trufflandier N et al. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 2001; 40: 265-272.